BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study

被引：0
|
作者：
Hu, X. [1 ,2 ,3 ]
Zheng, X. [4 ]
Mo, H. [1 ,2 ,3 ]
Cui, X. [4 ]
Ding, L. [5 ]
Tan, F. [6 ]
Hu, P. [4 ]
Shi, Y. [1 ,2 ,3 ]
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[4] Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[5] Bettapharma Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
[6] Bettapharma Pharmaceut Co Ltd, R&D Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1492P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study
    Hu, X.
    Zheng, X.
    Mo, H.
    Cui, X.
    Ding, L.
    Tan, F.
    Hu, P.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S474 - S474
  • [2] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.
    Hu, Xingsheng
    Zheng, Xin
    Mo, Hongnan
    Cui, Xinge
    Ding, Lieming
    Tan, Fenlai
    Hu, Pei
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
    Xingsheng Hu
    Xin Zheng
    Sheng Yang
    Lin Wang
    Xuezhi Hao
    Xinge Cui
    Lieming Ding
    Li Mao
    Pei Hu
    Yuankai Shi
    Journal of Hematology & Oncology, 13
  • [5] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
    Hu, Xingsheng
    Zheng, Xin
    Yang, Sheng
    Wang, Lin
    Hao, Xuezhi
    Cui, Xinge
    Ding, Lieming
    Mao, Li
    Hu, Pei
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [6] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [7] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Tsimberdiou, A. M.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Johne, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [9] A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Di Cara, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [10] PHASE I DOSE-ESCALATION STUDY OF ORAL SELECTIVE C-MET INHIBITOR EMD 1214063 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Hong, D. S.
    Amin, H. M.
    Fu, S.
    Piha-Paul, S. A.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Stinchi, S.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 154 - 154
12345